Press Releases
We’re Delivering the Promise of Healthier Lives.
CURE PHARMACEUTICALÂ
Press Releases
We specialize in optimal formulations to achieve targeted release and exposure of medications.​
CURE Pharmaceutical Announces Completion of FDA Pre-IND Review and Clinical Trial Plans for CUREfilm Blue
OXNARD, Calif., March 27, 2019
CURE Pharmaceutical Expands U.S. DEA Approval to Manufacture Pharmaceuticals Using Whole Cannabis Plant
OXNARD, Calif., March 12, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has broadened its U.S. Drug Enforcement Administration (DEA) license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic cannabidiol (CBD). This license allows CURE to take […]
National Healthcare Economics and Policy Expert Ruben Jose King-Shaw Jr. Joins CURE Pharmaceutical
The drug delivery leader taps former COO of U.S. Centers for Medicare & Medicaid Services to join growing Board OXNARD, Calif., January 29, 2019
CURE Pharmaceutical Appoints Chairman, Adds Member to Its Board of Directors
The revolutionary drug delivery leader taps global finance strategist, William (Bill) Yuan, to head growing Board, which now includes prominent biotech investor, Dr. Gene Salkind OXNARD, Calif., January 15, 2019
CURE Pharmaceutical To Present at Benzinga Cannabis Capital Conference
LOS ANGELES, Jan. 09, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that it will host an investor presentation at the Benzinga Cannabis Capital Conference at the Eden Roc Miami Beach Hotel in Miami on January 16, 2019 at 5pm.
CURE Pharmaceutical Secures U.S. DEA Approval to Manufacture Cannabinoid-based Pharmaceuticals
OXNARD, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has secured a new registration with the Drug Enforcement Administration (DEA) as a manufacturer authorized to handle Schedule 1 controlled substances. With this license, CURE will develop and manufacture cannabinoid-based pharmaceutical products using its […]
CURE Pharmaceutical Names Veteran Executive as Chief Financial Officer
OXNARD, Calif., Nov. 14, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has tapped Alex Katz to be the company
Prominent Biotech Investor Gene Salkind Adds Another $2M Investment in CURE Pharmaceutical
investOXNARD, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, has announced that the company secured a $2 million investment at $2.5 per share from Gene Salkind, a company advisor and biotech investor, bringing his total investment in the company to $3 million. In February 2018, […]
CURE Pharmaceutical to Present at CannX 2018 International Medical Cannabis Conference
OXNARD, Calif.
CURE Pharmaceutical to Present at the MicroCap Conference on October 1st and 2nd at Essex House
NEW YORK, NY
CURE Pharmaceutical Secures Patent for Oral Thin Film Containing Bioactive Cannabinoid Molecules
LOS ANGELES, September 25, 2018
This press release is a modified version of the official Sleep Club Press Release that can be found here. Please read the official release for more information. This version of the press release does not present any new information or information that is different from that contained in the official press release. It only serves to […]
CURE Pharmaceutical Expands Distribution of CUREfilm Technology with First Licensing Agreement
CURE grants cannabis leader rights to its proprietary drug delivery technology in markets around the world. LOS ANGELES, Sept. 05, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC:CURR), (“CURE”), an innovative drug delivery and development company, today announced that it entered into a multi-year licensing agreement for the first time with a leading international cannabis company. […]
Cure Pharmaceutical Plans to Acquire Cannabinoid-Based Drug Pipeline from Therapix Biosciences Ltd.
OXNARD, Calif., July 11, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTCQB:CURR), (“CURE”), an innovative drug delivery and development company, announced today that it has signed a term sheet with Therapix Biosciences Ltd. (Nasdaq:TRPX), (“Therapix”), a specialty, clinical-stage pharmaceutical company developing cannabinoid-based treatments, to acquire the non-pain assets of Therapix, subject to the completion of the […]
CURE Pharmaceutical to Present on the Increased Bioavailability for Cannabinoids Due to New Delivery Technologies at O
LOS ANGELES, June 05, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced that CEO Rob Davidson will be presenting at the O
CURE Pharmaceutical to Showcase Company Growth at the 8th LD Micro Invitational
LOS ANGELES, May 23, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced that it will be presenting at the 8th annual LD Micro Invitational on Monday, June 4th at 4 PM PT/ 7 PM ET at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. CEO Rob Davidson will be presenting […]
CURE Pharmaceutical Attracts Strategic Investment to Speed Its Cannabinoid Drug Delivery Production
OXNARD, Calif.
CURE Pharmaceutical Secures Two Patents for the Extraction and Purification of Bioactive Cannabinoid Molecules
LOS ANGELES, April 04, 2018 (GLOBE NEWSWIRE)
CURE Pharmaceutical Reports Strong Progress and Sets Growth Roadmap for Remainder of Year
OXNARD, Calif., April 03, 2018 (GLOBE NEWSWIRE)
CURE Pharmaceutical Announces Closing of $1 Million Bridge Financing and Prepares to Uplist to NASDAQ
OXNARD, Calif.
CURE Pharmaceutical to Participate in Hawaiian Cannabis Science Dinner & Dialogue Panel to Discuss Company
LOS ANGELES
Biopharmaceutical Veteran Joins CURE Pharmaceutical to Lead Manufacturing
LOS ANGELES
CURE Pharmaceutical Adds Healthcare Luminary To Advisory Board, Secures $1 Million Investment as a Bridge to Uplisting
OXNARD, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE)
CURE Pharmaceutical Adds New VP of Strategy and Business Development
LOS ANGELES
CURE Pharmaceutical Launches New Brand Focused on Patient Needs in Medication Delivery
OXNARD, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE)